|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||57.08 - 57.08|
|52-week range||57.08 - 84.04|
|Beta (5Y monthly)||0.94|
|PE ratio (TTM)||18.04|
|Forward dividend & yield||1.41 (2.47%)|
|Ex-dividend date||13 May 2022|
|1y target est||N/A|
Fresenius Medical's (FMS) first-quarter earnings benefit from strong performance across all the geographic regions and segments.
German healthcare group Fresenius's first-quarter profit exceeded market expectations on Wednesday, driven by growth in its generic infusion drugs unit in emerging markets. However, the group warned cost inflation and supply chain disruptions were likely to increase this year, fuelled by Russia's invasion of Ukraine. Fresenius's businesses include the Helios hospital chain, drugmaker Kabi, medical services firm Vamed and dialysis specialist Fresenius Medical Care (FMC).
Fresenius Medical's (FMS) My Reason campaign will help scientists understand genetic variations in patients with chronic kidney disease in a better way.